Treatment Decisions for Patients with HCV and CKDPremiere Date: Thursday, May 5, 2022
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Friday, May 5, 2023
Note: Credit Is No Longer Available
|Nancy Reau, MD (Moderator)
Professor of Medicine
Richard B. Capps Chair of Hepatology
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Rush University Medical Center
|Anthony Martinez, MD, AAHIVS, FAASLD
Associate Professor of Medicine
Jacobs School of Medicine
University at Buffalo
Medical Director, Hepatology
Erie County Medical Center
|Joseph K. Lim, MD (Reviewer/Advisor)
Professor of Medicine
Director, Clinical Hepatology
Vice-Chief, Section of Digestive Diseases
Yale University School of Medicine
New Haven, CT
The low rates of hepatitis C virus (HCV) screening in real-world practice indicate the existence of barriers that need to be overcome. In addition to the COVID-19 pandemic causing delays and/or discontinuations in many hepatitis elimination efforts, there are barriers on the provider level, such as communication challenges, low awareness of HCV, and poor knowledge of HCV screening recommendations. Patient-level barriers include lack of knowledge and awareness of HCV infection, confusion about transmission, and lack of insurance to pay for screening. It is essential that clinicians who treat patients with HCV are aware of these barriers and are equipped with strategies to overcome them in order to ensure screening and optimal management of all populations at risk for HCV infection.
This CMEO BriefCase will introduce a complex HCV case involving a patient with HCV and chronic kidney disease (CKD). Join Drs. Nancy Reau and Anthony Martinez as they dive deeper into treatment and management considerations for such patients, focusing on screening, diagnosis, and risk factors as well as the epidemiology and shared pathobiology of HCV and CKD.
At the end of this CE activity, participants should be able to:
- Implement CDC screening guidelines in practice to improve the detection and diagnosis of HCV.
Supported by an educational grant from Gilead Sciences, Inc.
U.S. and international physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in primary care
Through a mutual recognition agreement between the AMA and the UEMS-EACCME, European physicians completing an e-learning activity from a US-based ACCME-accredited CME provider can use AMA PRA Category 1 Credit™ toward their credit requirements. CME Outfitters is based in Radnor, Pennsylvania, USA. Please retain your certificate as proof of completion.
ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Reau reports the following financial relationships:
Consultant: AbbVie Inc.; Gilead Sciences, Inc.; Intercept; and Merck
Grants/Research Support: Genfit; Intercept; and Shire
Dr. Martinez reports the following financial relationships:
Advisory Board: AbbVie Inc.; Antios; Eisai; Gilead Sciences, Inc.; and Intercept
Consultant: AbbVie Inc.; Antios; Eisai; Gilead Sciences, Inc.; and Intercept
Research Support: AbbVie Inc. and Gilead Sciences, Inc.
Speakers Bureau: AbbVie Inc.; Eisai; and Gilead Sciences, Inc.
Dr. Lim (Reviewer/Advisor) reports the following financial relationships:
Research Support: Allergan; Celgene Corporation; Eiger BioPharmaceuticals, Inc.; GENFIT; Gilead Sciences, Inc.; Pfizer Inc.; and Viking Therapeutics
The following peer reviewer and CME Outfitters staff have no financial relationships to disclose:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).